Comparative Pharmacology
Head-to-head clinical analysis: BAQSIMI versus GVOKE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAQSIMI versus GVOKE KIT.
BAQSIMI vs GVOKE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BAQSIMI (glucagon) nasal powder is a hormone that increases blood glucose concentration by stimulating hepatic glycogenolysis and gluconeogenesis. It also relaxes smooth muscle of the gastrointestinal tract.
Glucagon acts as a hormone that raises blood glucose by promoting hepatic glycogenolysis and gluconeogenesis, and reducing glycogen synthesis. It also relaxes smooth muscle of the gastrointestinal tract.
3 mg intranasally as a single dose for severe hypoglycemia.
1 mg subcutaneously or intramuscularly as a single dose; may repeat once after 15 minutes if no response.
None Documented
None Documented
Glucagon has a short plasma half-life of approximately 8–18 minutes after IV administration. For nasal glucagon (BAQSIMI), systemic half-life is similar; clinical effect is brief, and rapid clearance limits duration.
Terminal elimination half-life: 8-15 minutes; clinical context: due to rapid clearance, continuous infusion or repeated dosing is required for sustained effect.
Primarily renal: metabolites and unchanged drug are excreted in urine. No significant biliary/fecal excretion data reported; glucagon is degraded in plasma, liver, and kidneys.
Primarily hepatic metabolism; renal excretion of metabolites; <10% unchanged in urine. Biliary excretion of metabolites is minimal.
Category C
Category C
Glucagon (Antihypoglycemic)
Glucagon (Antihypoglycemic)